Britvic plc (LON:BVIC – Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as GBX 1,038 ($13.19) and last traded at GBX 1,015 ($12.90), with a volume of 1433292 shares changing hands. The stock had previously closed at GBX 969.50 ($12.32).
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on BVIC. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Britvic in a report on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Britvic in a report on Tuesday, April 30th. They issued a “buy” rating and a GBX 1,040 ($13.21) target price on the stock. Finally, Numis Securities restated a “hold” rating and issued a GBX 900 ($11.44) price objective on shares of Britvic in a report on Thursday, April 11th.
Check Out Our Latest Research Report on Britvic
Britvic Stock Performance
Britvic Cuts Dividend
The business also recently declared a dividend, which will be paid on Friday, July 5th. Shareholders of record on Thursday, May 30th will be issued a dividend of GBX 9.50 ($0.12) per share. The ex-dividend date of this dividend is Thursday, May 30th. This represents a yield of 1.04%. Britvic’s dividend payout ratio (DPR) is presently 6,274.51%.
Britvic Company Profile
Britvic plc, together with its subsidiaries, manufactures, markets, distributes, and sells soft drinks in the United Kingdom, the Republic of Ireland, France, Brazil, and internationally. It provides fruit juices, syrups, squash, mineral water, sodas, mixers, and energy and flavored drinks. The company supplies water-coolers and bottled water; offers pension funding and financing services; and designs, installs, as well as engages in maintenance of integrated tap related solutions.
Read More
- Five stocks we like better than Britvic
- The How And Why of Investing in Oil Stocks
- McDonald’s Stock: Balancing Value and Innovation
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 6/17 – 6/21
- Investing in Commodities: What Are They? How to Invest in Them
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Britvic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Britvic and related companies with MarketBeat.com's FREE daily email newsletter.